Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2011. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility under the 2009 GlaxoSmithKline Performance Share Plan (PSP).
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to specific share transaction prices:
- Ordinary Share Sale Price: £11.77 per share (February 25, 2011).
- ADS Withholding Price: $38.13 per ADS (February 25, 2011).
Material Changes
The filing details the sale and withholding of shares by executive directors and other managerial personnel to meet tax liabilities following the vesting of PSP awards. No material changes to the company's overall financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a regulatory disclosure of insider trading activity compliant with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transactions occurred on February 25, 2011, and were notified on March 1, 2011.
- Shares were sold or withheld specifically to satisfy tax obligations arising from the vesting of performance shares.
- Executive Directors involved in Ordinary share sales include Mr. A. Witty (58,532 shares) and Mr. J. S. Heslop (21,468 shares).
- Executive Director Dr. M. M. Slaoui had 10,549 ADSs withheld.
- The filing does not contain financial performance data for the quarter or year.